Laboratory Medicine in the Era of Disruptive Technology
LMCE 2017 & KSLM 58th Annual Meeting
October 18-20, 2017
Grand Walkerhill Seoul, Korea
www.lmce-kslm.org

KSLM guideline: Korean perspectives and clinically important gene

Sollip Kim, M.D. [1,+], Yeo-Min Yun, M.D. [2,+], Hyo-Jin Chae, M.D. [3], Hyun-Jung Cho, M.D. [4], Misuk Ji, M.D. [5], In-Suk Kim, M.D. [6], Kyung-A Wee, M.D. [7], Woochang Lee, M.D. [8], Sang Hoon Song, M.D. [9], Hye In Woo, M.D. [10], Soo-Youn Lee, M.D. [11,*], and Sail Chun, M.D. [8]

[1+]Department of Laboratory Medicine, Paik Hospital, Inje University College of Medicine, Goyang; Department of Laboratory Medicine, Korea
[2+]Konkuk University Medical Center, Konkuk University School of Medicine, Seoul; Department of Laboratory Medicine, Korea
[3]College of Medicine, The Catholic University of Korea, Seoul; Department of Laboratory Medicine, Korea
[4]Konyang University Hospital, College of Medicine, Konyang University, Daejeon; Department of Laboratory Medicine, Korea
[5]Veterans Health Service Medical Center, Seoul; Department of Laboratory Medicine, Korea
[6]School of Medicine, Pusan National University, Pusan; Department of Laboratory Medicine, Korea
[7]Yonsei University College of Medicine, Seoul; Department of Laboratory Medicine, Korea
[8]University of Ulsan College of Medicine and Asan Medical Center, Seoul; Department of Laboratory Medicine, Korea
[9]Seoul National University Hospital and College of Medicine, Seoul; Department of Laboratory Medicine, Korea
[10]Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon; Department of Laboratory Medicine and Genetics, Korea
[11]Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Korea
[+]These authors contributed equally to this work.

Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. We aim to present the essentials of Korean Clinical Pharmacogenetic Testing and Application Guideline for more listeners to understand, although the original version of this article has been published on Laboratory Medicine Online. The guideline contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions. The pharmacogenetic tests discussed in the guideline are limited to clinical tests covered by the Korea health insurance medical care expenses for patient treatment. The recommendations for *CYP2C9 & VKORC1*, *CYP2C19*, *CYP2D6*, *TPMT, NAT2*, *UGT1A1*, *EGFR, HER2 (ERBB2), and KRAS* genotype tests have been prepared. Pharmacogenetic tests for drug development or research have been excluded. The guidelines were developed according to the methodology of the Adaptation Process for Developing Korean Clinical Practice Guidelines Ver. 2.0. The guideline aims to improve the utility of pharmacogenetic testing in routine clinical settings.